Breast cancer institute of Fudan University Cancer Hospital
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TCb vs EC-T in High Risk ER+/HER2- Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Recruiting | Phase 3 | 2026-09-28 | NCT05901428 | |
| Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer | Breast Cancer Metastatic | Active, not recruiting | Phase 2 | 2026-09-16 | NCT05759572 | |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-09-03 | NCT06649331 | |
| Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-08-19 | NCT04383275 | |
| Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-03-25 | NCT05806060 | |
| Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases | HER2-negative Breast Cancer | Not yet recruiting | Phase 2 | 2026-03-12 | NCT07466927 | |
| Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-01-21 | NCT05909332 | |
| A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2025-07-16 | NCT05862064 | |
| JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Phase 2 | 2024-12-12 | NCT06731153 | |
| Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | BRCA-Mutated Breast Carcinoma; HER2-negative Breast Cancer | Recruiting | Phase 2 | 2024-12-12 | NCT06516289 | |
| The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer | Breast Cancer Female | Not yet recruiting | Not applicable | 2024-10-10 | NCT06635096 | |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2024-10-04 | NCT05594095 | |
| Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2024-03-22 | NCT05861271 | |
| A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2024-02-21 | NCT05999149 | |
| Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2024-02-06 | NCT05760378 | |
| PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer | Breast Cancer Metastatic | Recruiting | Phase 2 | 2024-02-06 | NCT05759546 |